Related Experiment Video

Updated: May 16, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

[Successive cutaneous adverse reactions to nilotinib and imatinib in a single patient]

M Lamchahab1, M Qachouh, F Hali

  • 1Service d'hématologie et d'oncologie pédiatrique, hôpital 20-Août-1953, CHU Ibn Rochd, 1, quartier des hôpitaux, Casablanca, Maroc. mlamchahab@hotmail.fr

Annales De Dermatologie Et De Venereologie
|December 15, 2012
PubMed
Abstract

Insights

Skin reactions to tyrosine kinase inhibitors (TKIs) are common in chronic myeloid leukemia (CML) treatment. This case highlights potential cross-sensitivities between different TKIs, complicating treatment for some CML patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Dermatology

Background:

  • Tyrosine kinase inhibitors (TKIs) have revolutionized cancer therapy, particularly for chronic myeloid leukemia (CML).
  • Skin toxicity is a frequent adverse effect of TKIs, impacting treatment adherence.
  • Understanding TKI-induced skin reactions is crucial for managing CML patients.

Observation:

  • A CML patient developed skin lesions after imatinib (IM) treatment.
  • Subsequent treatment with nilotinib also triggered severe skin reactions, resembling erythema multiforme.
  • Skin biopsy confirmed a drug-induced eruption.

Findings:

  • The patient experienced recurrent, severe skin reactions upon sequential TKI therapy (imatinib and nilotinib).
  • These reactions necessitated treatment discontinuation, posing a challenge for managing CML.
  • Cross-sensitivity between different TKIs may occur, despite initial assumptions of infrequency.

Implications:

  • Substitution with second-generation TKIs may not always resolve intolerance issues due to potential cross-reactivity.
  • Managing CML patients with TKI-induced skin toxicities requires careful consideration of alternative treatments.
  • Further research into TKI-related dermatological adverse events is warranted to optimize CML patient care.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...